Cyclin E-Cdk2 has long been considered an essential and master regulator of progression through G1 phase of the cell cycle. Although recent mouse models have prompted a rethinking of cyclin E function in mammals, it remains clear that cyclin E impacts upon many processes central to cell division. Normal cells maintain strict control of cyclin E activity, and this is commonly disrupted in cancer cells. Moreover, cyclin E deregulation is thought to play a fundamental role in tumorigenesis. In this review, we discuss the regulation and functions of cyclin E in normal and neoplastic mammalian cells.
Introduction
Cyclin-dependent kinases control cell cycle transitions. These enzymes contain two subunits, a catalytic Cdk subunit and a regulatory cyclin subunit that activates the Cdk. In mammalian cells, nearly 20 cyclins and 10 Cdks have been described (although not all participate in cell cycle control), and each phase of the cell cycle has a unique profile of cyclin-Cdk activity. Two types of cyclin-Cdks regulate the transit of mammalian cells from quiescence into S phase: the D-type cyclins, which activate Cdk4/6, and cyclin E, which activates Cdk2 (reviewed in Sherr, 1994) . Cyclin E is a nuclear protein that was first identified through its ability to complement the proliferative defects in cyclin-deficient yeast cells (Koff et al., 1991; Lew et al., 1991) . A second member of the cyclin E family, termed cyclin E2, shares 47% overall amino-acid homology with cyclin E, and is 70% homologous within the cyclin box (Lauper et al., 1998; Zariwala et al., 1998; Gudas et al., 1999) . Although specific studies on cyclin E2 are limited, the two cyclin E proteins exhibit very similar activities and regulation. This review will primarily cover cyclin E1 (referred to as cyclin E below); cyclin E2 will be specifically addressed when relevant.
Cyclin E-Cdk2 activity is highest in G1-S cells and lowest in quiescent cells (Dulic et al., 1992; Koff et al., 1992; Ekholm et al., 2001) . This periodicity results from many factors including transcriptional and post-transcriptional control of cyclin E abundance, the binding of Cip/Kip Cdk inhibitors (reviewed in Sherr and Roberts, 1995) and modification of Cdk2 activity by inhibitory and activating phosphorylations. These multiple layers of control insure that cyclin E activity is tightly regulated during normal cell cycles. In contrast, cyclin E-Cdk2 is often deregulated in cancer cells, and this likely contributes to the development of cancer. This review will cover current models of normal and neoplastic cyclin E regulation and function in mammalian cells.
Regulation of cyclin E abundance

Transcriptional control
Cyclin E is a component of the retinoblastoma (Rb) pathway, in which progressive phosphorylation of Rb by cyclin D-Cdk4/6 and cyclin E-Cdk2 releases E2F and promotes S-phase entry (reviewed in Sherr and McCormick, 2002) . (Figure 1a ). E2F is a transcription factor that regulates the expression of genes involved in S phase (reviewed in Dyson, 1998) . Cyclin E itself is an E2F target gene and the cyclin E promoter contains defined E2F binding sites (Ohtani et al., 1995; Geng et al., 1996; Le Cam et al., 1999) . As cyclin E-Cdk2 phosphorylates (and inactivates) Rb, cyclin E may reinforce its own expression through a positive feedback loop. Conditions that inactivate Rb, or otherwise increase E2F activity, thus increase cyclin E transcription. A possible consequence of this feedback is that once cyclin E-Cdk2 becomes active, Rb phosphorylation may be rendered partially independent of the mitogenic control that governs cyclin D expression. The regulation of cyclin E transcription by E2F proteins has been evolutionarily conserved (Duronio and O'Farrell, 1995) , and cyclin E is an essential mediator of E2F-induced S-phase entry in Drosophila (Knoblich et al., 1994; Duronio et al., 1996) . The specific role of E2F-driven cyclin E transcription in mammalian cell cycle control is less clear, and E2F-independent cyclin E transcription has also been described . Although E2F plays the major known role in cyclin E transcriptional control, other transcription factors might regulate cyclin E in other biologic contexts. For example, cyclin E is a direct transcriptional target of LRH-1 in pancreatic and hepatic cells (Botrugno et al., 2004) .
The cyclin E mRNA is also regulated by alternative splicing. The full-length human cyclin E protein contains 409 amino acids, and several cyclin E protein isoforms resulting from differential cyclin E mRNA splicing have been described (Koff et al., 1991; Dulic et al., 1992; Sewing et al., 1994; Ohtsubo et al., 1995; Mumberg et al., 1997; Porter and Keyomarsi, 2000) . The functional and physiologic relevance of differential cyclin E splicing is unknown. a) Transcriptional and proteolytic regulation of cyclin E. Phosphorylation of Rb by cyclin D-Cdk and cyclin E-Cdk complexes releases sequestered E2F and increases cyclin E transcription because the cyclin E promoter contains E2F binding sites. Cyclin E transcription is also activated by LRH-1 in some cell types. Cyclin E proteolysis is mediated through two proteasomal pathways. Monomeric cyclin E is ubiquitinated via a Cul-3-dependent pathway that likely requires an unknown BTB protein. Cyclin E that has bound to Cdk2 is degraded by the SCF Fbw7 , and this is regulated by cyclin E phosphorylation. Some of these phosphorylations are prevented by the p27 and p21 Cdk inhibitors. (b) Cyclin E phosphorylation sites. The sites of known N-and C-terminal cyclin E phosphorylation are indicated by their amino-acid location. Shaded circles denote phosphorylation sites implicated in cyclin E protein turnover. The kinases associated with each site, as well as the MRAIL and VDCLE motifs, are also indicated
Proteolysis
Cyclin E is an unstable protein that is degraded by two distinct pathways involving the ubiquitin-proteasome system ( Figure 1a ). The accessibility of cyclin E to these proteolytic pathways depends upon whether cyclin E is monomeric or bound to Cdk2. The first pathway involves the Cul-3 protein (at least in early embryogenesis), and exclusively targets monomeric cyclin E (Clurman et al., 1996; Singer et al., 1999) . Monomeric cyclin E is exceptionally labile and rapidly overaccumulates when the proteasome is inhibited. Cul-3 binds to monomeric cyclin E, but not to cyclin E in complex with Cdk2, and the determinants that regulate the Cul-3-cyclin E interaction are unknown. Although Cul-3 only targets monomeric cyclin E, Cul-3 disruption in the mouse causes early embryonic lethality associated with cyclin E overaccumulation (Singer et al., 1999) , and this indicates that Cul-3 plays an important role in regulating endogenous cyclin E abundance. Recent work showing that a large family of BTB proteins function as the substrate adaptor proteins within Cul-3 ubiquitin ligases (Furukawa et al., 2003; Pintard et al., 2003; Xu et al., 2003) suggests that new insights into the Cul-3 pathway of cyclin E degradation will soon be possible once the BTB protein that binds to monomeric cyclin E has been identified.
The second pathway of cyclin E degradation involves the SCF-Fbw7 ubiquitin ligase. SCF complexes are multiprotein ubiquitin ligases that degrade a number of key cell cycle proteins (reviewed in Patton et al., 1998; Deshaies, 1999) . The F-box proteins are the SCF components that function as substrate receptors (Skowyra et al., 1997) , and usually bind to substrates only after they have been phosphorylated within domains called Cdc-phosphodegrons (CPDs) (Orlicky et al., 2003) . The F-box proteins associate with the rest of the SCF complex by binding to Skp1 through their Fbox motifs, and SCF complexes bring substrates into physical proximity with the core ubiquitination enzymes.
Initial studies found that degradation of cyclin E bound to Cdk2 was strongly influenced by cyclin E phosphorylation and Cdk2 activity (Clurman et al., 1996; Won and Reed, 1996) . Three groups subsequently described Fbw7 (or its Drosophila homologue, Ago) as the F-box protein that binds to and promotes the ubiquitination of phosphorylated cyclin E (Koepp et al., 2001; Moberg et al., 2001; Strohmaier et al., 2001) . The interactions of Fbw7 and cyclin E are complex and regulated by several cyclin E phosphorylations. Some of these sites are autophosphorylated (see below), and this explains why the stability of cyclin E in complex with Cdk2 is highly dependent upon the catalytic activity of these complexes. That is, Fbw7 cannot degrade cyclin E within inactive complexes, such as those that contain p21 or p27, because it lacks required phosphorylations. Normal cells contain a substantial pool of cyclin E that is bound to p21 and cannot be degraded by Fbw7. The physiologic role of this stable but catalytically inactive cyclin E-Cdk2 is unknown. T380 and T62 are the most thoroughly characterized phosphorylations that regulate the binding of Fbw7 to cyclin E, and each of these sites may comprise an independent CPD. Phosphorylated peptides representing either T62 or T380 directly bind to Fbw7, and simultaneous mutation of both T62 and T380 is required to block completely Fbw7 binding and cyclin E ubiquitination in vitro (Koepp et al., 2001; Strohmaier et al., 2001; Ye et al., 2004) . T62 and T380 also cooperatively regulate Fbw7-driven cyclin E turnover in vivo, although mutation of either site significantly cripples cyclin E turnover (Strohmaier et al., 2001; Welcker et al., 2003) . In addition to comprising an independent CPD, T62 may also regulate cyclin E stability by modulating T380 phosphorylation (Ye et al., 2004) . The physiologic role of these two independent cyclin E CPDs is an interesting but largely unanswered question. One possibility is that these two sites may allow Fbw7 to bind to cyclin E after it becomes phosphorylated in response to different signaling pathways that promote either T62 or T380 phosphorylation (see below). Knockin mice containing mutations of T380, or both T62 and T380, should help in answering these questions.
Two additional carboxyl-terminal cyclin E phosphorylations (S372 and S384) also regulate Fbw7-driven cyclin E turnover (Welcker et al., 2003) . S384, a previously unrecognized autophosphorylation site, plays a major role in regulating Fbw7-driven cyclin E turnover, and is the site that directly links Cdk2 activity to cyclin E stability. The mechanisms through which S384 phosphorylation regulates cyclin E stability are still unclear, but may involve direct regulation of Fbw7 binding as well as cyclin E subcellular localization (Ye et al., 2004) . S372 phosphorylation plays a subtler role in regulating cyclin E stability, and its mechanism of action is also unknown.
Cyclin E2 proteolysis is probably regulated similarly to cyclin E1. Cyclin E2 is unstable and accumulates upon proteasome inhibition, and Cdk2 and p27 binding prevent its turnover (Lauper et al., 1998; Zariwala et al., 1998; Gudas et al., 1999) . Moreover, mutation of T392, the residue corresponding to cyclin E T380, stabilizes cyclin E2. The T392 sequence conforms to the CPD consensus, but Fbw7 binding to cyclin E2 has not yet been reported.
The complex regulation of cyclin E turnover suggests that it is critically important that cyclin E in catalytically active complexes is rapidly degraded. However, the ramifications of impaired cyclin E degradation are less dramatic than other proteins such as cyclin B, which prevents mitotic exit when rendered nondegradable. One consequence of defective cyclin E degradation is genetic instability (Spruck et al., 1999; Minella et al., 2002) , and this may play a critical role in cyclin E-associated cancers (see below). Stable mutants of cyclin E also induce more severe cell cycle anomalies than wild-type cyclin E (Minella et al., 2002; Welcker et al., 2003) , and it is likely that timely cyclin E degradation is required for the proper execution of many processes involved in cell division.
Regulation of cyclin E phosphorylation
Cyclin E contains two clusters of phosphorylation sites, an N-terminal cluster (S58, T62, S75 and S88) and a Cterminal cluster (S372, T380, S384), which have been studied by phosphopeptide mapping, mass spectrometry and phospho-specific antibodies (Figure 1b ). S58 is phosphorylated by glycogen synthase kinase 3 (GSK-3), and like many GSK-3 sites that require a priming phosphorylation in the þ 4 position; this depends upon T62 phosphorylation (Welcker et al., 2003) . Although T62 phosphorylation regulates cyclin E stability, S58 phosphorylation does not, and its function is unknown. T62 phosphorylation has not been directly observed by either phosphopeptide mapping or mass spectrometry, and this is probably due to the size and cysteine-rich nature of the T62-containing peptide. However, T62 phosphorylation has been directly revealed by T62-specific phosphoantibodies, and this appears to be due to Cdk2 and at least one additional kinase (BE Clurman, unpublished observations).
Little is known about the remaining N-terminal phosphorylations. S75 is the major phosphorylation site of cyclin E autophosphorylation in vitro, but it has not been observed in vivo (Welcker et al., 2003) . Although S75 and S384 are both autophosphorylation sites, they are not proline directed, and thus are not consensus Cdk sites. Instead, they contain a novel motif (PxSxxK) that may represent a distinct class of Cdk sites, perhaps involving sites in cyclins that are phosphorylated in cis by their associated Cdks. S88 has thus far been detected only by mass spectrometric analysis of ectopic cyclin E protein expressed in vivo (Ye et al., 2004) .
The C-terminal residues that regulate cyclin E stability are phosphorylated by at least three different kinases. Although T380 was once believed to be strictly an autophosphorylation site, GSK-3 also phosphorylates T380 (Welcker et al., 2003) . Despite the presence of S384 in the þ 4 position, phosphorylation of T380 does not require a priming S384 phosphorylation. T380 is also phosphorylated by Cdk2 (Won and Reed, 1996; Welcker et al., 2003) and the relative roles of GSK-3 and Cdk2 in T380 phosphorylation in different biologic contexts is an important unresolved issue. Unlike T380, S384 is only phosphorylated by Cdk2, and inhibiting Cdk2 activity completely abrogates S384 phosphorylation. Finally, neither Cdk2 nor GSK-3 phosphorylates S372, and the S372 kinase has not yet been identified.
What are the implications of these multiple cyclin E phosphorylations for cell cycle control? Previous models of G1 control have depicted the D-type cyclins (whose synthesis, function and stability is mitogen sensitive) as the primary means through which mitogenic signaling pathways gain access to cell cycle control. However, the finding that GSK-3 (which is itself under mitogen control) and other unknown kinases phosphorylate cyclin E on important regulatory sites suggests that mitogenic signal transduction pathways also impact upon the cell cycle through control of cyclin E stability and/or activity. Thus, rather than simply oscillating with each cell cycle, cyclin E may instead integrate information transmitted by diverse signal transduction pathways and couple these pathways to cell cycle control.
Cyclin E functions and substrates
Although recent work describing the phenotypes (or lack thereof) of cyclin E or Cdk2 ablation in the mouse has forced a re-evaluation of cyclin E function in mammals (see below), many previous studies have provided significant insights into cyclin E function (Figure 2 ). The findings that excess cyclin E activity causes cells to progress through G1 phase more quickly (Ohtsubo and Roberts, 1993; Resnitzky et al., 1994) , in combination with data showing that cyclin E-Cdk 2 inhibition prevented S-phase entry (Tsai et al., 1993; van den Heuvel and Harlow, 1993; Ohtsubo et al., 1995) , led to the dogma that cyclin E is required and rate limiting for S phase entry. These conclusions were reinforced by many studies showing that CDK inhibitor proteins caused a G1 arrest that was likely due to cyclin E-Cdk2 inactivation (reviewed in Sherr and Roberts, 1999) . Although G1 is shortened by excess cyclin E activity, Sphase progression is prolonged (Ohtsubo and Roberts, 1993; Minella et al., 2002; Ekholm-Reed et al., 2004b) , and this may result from the prevention of prereplication complex formation (Ekholm-Reed et al., 2004b) . Ectopic cyclin E expression also causes decreased mitogen requirements, decreased cell size and increased saturation density. In sum, a large amount of data support the idea that cyclin E-Cdk2 activity plays a critical role in G1 progression.
Perhaps, the best-studied cyclin E function is its role in Rb pathway signaling. In fact, several lines of evidence indicate that cyclin E activation is the essential downstream effector of Rb pathway activation. For example, ectopic cyclin E over-rides the cell cycle arrest imposed by an Rb mutant protein that cannot be phosphorylated by cyclin-Cdks (Lukas et al., 1997). Moreover, replacement of the endogenous cyclin D1 coding sequences with a cyclin E cDNA by homologous recombination in mice rescues the phenotypes of cyclin D1 deletion, indicating that the only essential cyclin D function may be to activate cyclin E (Geng et al., 1999) . Thus, cyclin E-Cdk2 activity can provide most (or all) of the essential functions enabled by Rb inactivation.
Cyclin E-Cdk2 presumably exerts most (see below) of its biologic activities by phosphorylating its substrates. Two motifs (Figure 1b) within the cyclin E protein regulate substrate binding: (1) MRAIL (residues 130-134), which is within the amino-terminus of the cyclin box and mediates binding to substrates containing RXL domains (Adams et al., 1996; Chen et al., 1996; Schulman et al., 1998; Furstenthal et al., 2001) and (2) VDCLE (residues 274-278) (Kelly et al., 1998) , which is similar to the sequence LXCXE found in D-type cyclins and viral oncoproteins, and regulates binding to pocket proteins (Rb, p107, p130) (Dowdy et al., 1993) . A number of RXL-containing proteins are themselves cell cycle proteins, and in at least two cases, phosphorylation by cyclin E-Cdk2 inactivates RXL proteins that normally inhibit G1 progression (Rb and p27Kip1). As described above, cyclin E-Cdk2-mediated Rb phosphorylation inactivates Rb by facilitating E2F release. In the case of p27, phosphorylation of T187 by cyclin E-Cdk2 stimulates p27 degradation in S phase by the SCF-Skp2 ubiquitin ligase (Vlach et al., 1996; Sheaff et al., 1997; Carrano et al., 1999) . P27 is thus both an inhibitor and a substrate of cyclin E-Cdk2, and the factors that determine which of these functions it performs are unclear.
Additional proteins that regulate cell division are also cyclin E-Cdk2 substrates. NPAT/p220 is a transcription factor that controls cell cycle-dependent histone gene transcription, and phosphorylation of NPAT by cyclin E-Cdk2 stimulates histone mRNA synthesis (Ma et al., 2000; Zhao et al., 2000) . Cyclin E-Cdk2 also phosphorylates CBP /p300 at G1/S, and this activates its histone acetyl transferase activity (Ait-Si-Ali et al., 1998). The role of CBP activation in G1/S is unknown, but may involve its functions as a cofactor for many transcription factors including E2F. Interestingly, cyclin E-Cdk2 phosphorylates E2F-5 and increases its transcriptional activity, and this may be due to CBP/p300 recruitment (Morris et al., 2000) .
Cyclin E-Cdk2 also phosphorylates centrosomal proteins that regulate centrosome duplication. In fact, recent work has defined a centrosomal localization signal within cyclin E that plays an essential role in cyclin E-instigated S-phase entry, even under conditions in which cyclin E could not activate Cdk2 (Matsumoto and Maller, 2004) . Phosphorylation of nucleophosmin on T199 by cyclin E-Cdk2 promotes nucleophosmin release from the centrosome, thereby stimulating centrosome duplication (Okuda et al., 2000; Tokuyama et al., 2001) . CP110 is another centrosomal cyclin E substrate that plays an essential, but poorly understood role in the centrosome cycle (Chen et al., 2002) .
Finally, cyclin E cooperates with Cdc6 to allow prereplication complexes to form during the G0-S transition. This likely involves the binding of MCM proteins to replication origins, and it was proposed that cyclin E-Cdk2 creates a 'window of opportunity' for MCM loading in G0-G1, which is subsequently closed by cyclin A-Cdk2 in S phase (Coverley et al., 2002) . Moreover, excess cyclin E-Cdk2 activity prevents the loading of MCM proteins onto origins during telophase and G1 (Ekholm-Reed et al., 2004a) . However, although it is thought that MCM proteins themselves are cyclin E substrates, this has not yet been shown. In sum, several cyclin E-Cdk2 substrates involved in cell division are now known. This short list is certainly incomplete, and proteomic screens are likely to uncover many new cyclin E-Cdk2 substrates in the near future.
New insights into cyclin E-Cdk2 function from knockout mice
The mass of accumulated data along the lines outlined led to the model that cyclin E-Cdk2 is an essential and master regulator of the G1-S transition, and that cyclin E executes its cell cycle functions via Cdk2-dependent phosphorylation of its substrates. However, studies utilizing cyclin E or Cdk2-null mice indicate that even these most basic assumptions may be incorrect. The Sicinski and Amati labs created mice lacking both cyclin E1 and cyclin E2, and found that for the most part, these mice developed normally, and that cyclin E-null fibroblasts proliferate reasonably well (Geng et al., 2003; Figure 2 Normal and neoplastic cyclin E function. Processes that are regulated (or deregulated) by cyclin E-Cdk2 activity in normal and cancer cells are shown. Some known direct cyclin E-Cdk2 substrates are also indicated (see text). NPM, nucleophosmin; Rb, retinoblastoma protein; CBP, CREB-binding protein; NPAT, nuclear protein mapped to the AT locus Parisi et al., 2003) . However, despite the shockingly normal cell division in the absence of cyclin E, these animals do have phenotypes that provide intriguing insights into cyclin E function.
Firstly, the cyclin E-null animals exhibit defective endoreduplication in both giant trophoblast cells and megakaryocytes. In fact, the trophoblastic failure caused early embryonic lethality, and cyclin E-null animals were only obtained after tetraploid complementation rescue. Previous studies in flies suggested an intimate relationship between cyclin E expression, MCM proteins and endoreduplication (Follette et al., 1998; Su and O'Farrell, 1998; Weiss et al., 1998) , and cyclin E deregulation has been linked to megakaryopoiesis in mammals as well (Garcia et al., 2000) . The knockout mice extend these observations, and show that cyclin E is required for endocycles, and this probably involves defective MCM loading.
Although asynchronous cell division is largely normal in cyclin E1/E2-null fibroblasts, these cells exhibit a profound defect in cell cycle entry from quiescence. These data fit well with previous in vitro studies demonstrating a specific requirement for cyclin ECdk2 in loading MCM protein during G0-S (Coverley et al., 2000) . Surprisingly, despite the failure of serumstimulated cyclin E-null cells to enter S phase, these cells accumulate active cyclin A-Cdk complexes, indicating that cyclin E and cyclin A perform nonredundant functions as cells exit quiescence. Finally, reminiscent of previous studies from the Sicinski lab indicating that cyclin D1 ablation renders mammary epithelial cells resistant to transformation by Ras (Yu et al., 2001) , cyclin E-null MEFs are resistant to oncogenic transformation in vitro.
Although there is still much to be learned about cyclin E function from these animals, several conclusions seem inescapable: (1) cyclin E is not required for cell division, (2) cyclin E performs a specialized function as cells exit quiescence, (3) cyclin E is intimately involved with endoreduplication and (4) cyclin E-null cells resist oncogenic transformation. Do these data render the previous decade of cyclin E research irrelevant? Certainly not, although they show that cyclin E expression is dispensable for cell division, this does not eliminate a key physiologic role for cyclin E in normal cell division. That is, although redundant activities may substitute for its loss, cyclin E may play a fundamental role in G1 progression when it is present in wild-type cells.
Concurrent with this work, two groups (Barbacid, Kaldis) disabled cyclin E-Cdk2 by making Cdk2 knockout mice, and found that these animals also developed almost normally (Berthet et al., 2003; Ortega et al., 2003) . Although the obvious prediction was that the phenotypes of cyclin E-null and Cdk2 mice would largely overlap, the Cdk2-null animals displayed none of the defects described in the cyclin E-null mice. There were no anomalies in either trophoblasts or megakaryocytes, quiescent Cdk2-null MEFS entered S phase after serum stimulation (although the Kaldis group found this to be modestly delayed), and Cdk2-null MEFS were transformed by oncogenes (albeit somewhat less efficiently than wild-type cells) using the same assay that demonstrated that cyclin E-null MEFs were not. Both groups also found an unexpected role for Cdk2 in meiosis leading to sterility, but the mechanistic basis for the requirement for Cdk2 in meiosis is not known.
What might account for the unanticipated phenotypic discordance between the cyclin E and Cdk2-null mice? The leading suspicion upon hearing these results is that a redundant kinase must be able to substitute for Cdk2 and form active complexes with cyclin E. However, no cyclin E kinase activity was found in the Cdk2-null mice, so, if present, it is below detectable levels. Moreover, Cdk2 and Cdk3 are the only kinases known to associate with cyclin E in vivo, and laboratory mice contain a mutation that prevents Cdk3 expression (Ye et al., 2001) . Thus although once unthinkable, it seems likely that cyclin E may have Cdk2-independent functions that account for some of the phenotypes resulting from its loss. This idea is supported by the findings that a cyclin E mutant that cannot activate Cdk2 still promotes Sphase entry if its centrosomal localization is maintained (Matsumoto and Maller, 2004) , as well as data indicating that kinase-defective cyclin E mutants are transforming in vitro (Geisen and Moroy, 2002) . Finally, it is important to reinforce the idea that perhaps the essential lesson to be learned from the cyclin E and Cdk2 knockout mice stems from the lack of a phenotype, rather than phenotypic differences between the two models. That is, mammalian mitotic cell cycles do not require cyclin E-Cdk2 activity, and in this respect, both the cyclin E and Cdk2 ablations lead us to the same conclusion.
Cyclin E and cancer
Cyclin E expression in human cancers
Cyclin E has been extensively studied in human cancers. Many cancers overexpress cyclin E protein or mRNA including carcinomas (breast, lung, cervix, endometrium, gastrointestinal tract), lymphoma, leukemia, sarcomas and adrenocortical tumors (Wolowiec et al., 1996; Yasui et al., 1996a, b; Iida et al., 1997; Molendini et al., 1998; Dong et al., 2000; Fukuse et al., 2000; Erlanson and Landberg, 2001; Muller-Tidow et al., 2001; Schraml et al., 2003; Tissier et al., 2004) . Several mechanisms deregulate cyclin E expression in tumors. A large number of oncogenes function within the mitogenic signal transduction pathways that regulate the Rb pathway, and oncogenic mutations within these pathways may increase cyclin E abundance via increased E2F activity. The most common means of activating cyclin E expression in cancers may thus involve mutations in regulatory pathways, rather than within cyclin E itself.
Although infrequent, cyclin E gene amplification occurs in human cancer cell lines and primary cancers. Several series have reported cyclin E amplification in primary endometrial, ovarian, colorectal, breast and gastric cancers with frequencies ranging from approximately 2 to 20% (Keyomarsi and Pardee, 1993; Leach et al., 1993; Akama et al., 1995; Kitahara et al., 1995; Marone et al., 1998; Cassia et al., 2003) . In some cases, cyclin E amplification was shown to cause elevated cyclin E mRNA expression. A recent study using tissue microarrays demonstrated cyclin E gene amplifications in additional neoplasms including rhabdomyosarcoma, pheochromocytoma, and carcinomas involving the ovary, uterus, bladder and gastrointestinal tract (Schraml et al., 2003) .
Disrupted proteolysis is another mechanism that deregulates cyclin E in cancers. Fbw7 loss-of-function mutations were originally described in cancer cell lines (Moberg et al., 2001; Strohmaier et al., 2001) , and have now been found in primary endometrial, pancreatic and colon cancers (Calhoun et al., 2003; Rajagopalan et al., 2004, #186; Spruck et al., 2002) . In many of these tumors, Fbw7 sustains classic two-step mutations, in which an Fbw7 allele (which resides within 4q32) is lost, and the remaining allele is inactivated by intragenic point mutations. The prevalence of Fbw7 mutations in tumors is not known, although some series indicate that 4q32 loss occurs in up to 30% of solid tumors (Spruck et al., 2002) . These types of mutations leave little doubt that Fbw7 is a human tumor suppressor. It was thus somewhat surprising that initial reports found that mice in which a single Fbw7 allele is deleted are not tumor prone (Tetzlaff et al., 2004; Tsunematsu et al., 2004) . However, a more recent study did find that Fbw7 functions as a p53-dependent haploinsufficient tumor suppressor when mice are irradiated (Mao et al., 2004) .
It is widely assumed that Fbw7 loss promotes tumorigenesis primarily through its affects on cyclin E. However, with the exception of work implicating cyclin E in Fbw7-associated genetic instability (see below), this idea remains largely unproven. In fact, one study found poor correlation between Fbw7 loss and cyclin E abundance in human tumors, although increased amounts of phosphorylated cyclin E were detected in these tumors (Spruck et al., 2002) and subsequent work documented cyclin E misregulation during the cell cycle (Ekholm-Reed et al., 2004b) . One explanation is that only the fraction of catalytically active (and thus hyperphosphorylated) cyclin E was stabilized by Fbw7 loss in these tumors. Another possibility, however, is that Fbw7 loss deregulates oncogenic targets other than cyclin E. For example, Fbw7 targets c-Myc for degradation, and this requires c-Myc phosphorylation on T58 by GSK-3 Yada et al., 2004) . T58 is the most frequently mutated c-Myc residue in lymphomas, and oncogenic c-Myc activation is likely to be an important mechanism of Fbw7-associated cancer. Other oncogenic Fbw7 targets include Notch (Gupta-Rossi et al., 2001; Wu et al., 2001 ) and c-Jun (Nateri et al., 2004) . Deregulated Aurora A activity has also been proposed as a mechanism of genetic instability in Fbw7 þ /À mice, although Aurora A has not been shown to be a direct Fbw7 substrate (Mao et al., 2004) .
In principle, additional mechanisms could also impair cyclin E degradation in cancer cells. For example, regulatory cyclin E phosphorylations could be inhibited by mutation of the phosphorylated residues, or by modified activity of the phosphorylation pathways. However, no mutations of the phosphorylation sites have been reported, nor have there been any comprehensive studies of cyclin E phosphorylation in cancer cells. Finally, the Cul-3 pathway could be targeted for mutation, although again there are no reports that address this possibility.
Cyclin E expression has been evaluated as a prognostic marker, and breast cancer has been most thoroughly studied (Keyomarsi et al., 1994; Dutta et al., 1995; Nielsen et al., 1996; Porter et al., 1997; Donnellan et al., 2001; Han et al., 2003; Rudolph et al., 2003; Span et al., 2003; Lindahl et al., 2004; Porter et al., 2004) . Most workers found that high cyclin E expression correlates with clinical outcome. For example, Porter et al. reported that high cyclin E expression was an independent prognostic factor that correlated with worse patient outcome in young women with breast cancer. A subset of these tumors had discordant cyclin E expression and proliferation indices (e.g. Ki-67), indicating that the cyclin E expression did not simply reflect increased proliferation. In other studies, however, cyclin E expression largely correlated with proliferative markers (Rudolph et al., 2003) , and the idea that cyclin E is an independent marker of survival has also been challenged (Span et al., 2003) . The basis of these discrepancies is not clear, but may involve heterogeneous patient populations and technical differences related to sample handling and/or immunocytochemical technique.
Keyomarsi and colleagues recently reported a highly significant association between cyclin E and survival in breast cancer. In their multivariate analysis of 395 women, high cyclin E expression was even more predictive of patient outcome than markers currently used for clinical decision making including hormone receptor status and lymph node involvement (Keyomarsi et al., 2002) . This was most evident for patients with early-stage cancers: 0/102 patients with stage I disease and low cyclin E expression, but 12/12 of the stage I patients with high cyclin E expression, had died within 5 years of diagnosis. One novel aspect of this study was that cyclin E expression was assayed by Western blotting, and that it specifically examined lowmolecular-weight isoforms of cyclin E. The Keyomarsi group has championed the idea that these isoforms are unique to cancer cells because of aberrant proteolytic processing, and that they are hyperactive, at least in part because they resist inhibition by Cip/Kip proteins (Porter et al., 2001; Akli et al., 2004) . Moreover, they suggest that the reason for the particularly strong prognostic significance of this study is their use of antibodies and assays that can detect truncated cyclin E isoforms. If others confirm these results, cyclin E expression (perhaps by Western blotting) may soon become an important clinical tool for determining breast cancer treatment. Cyclin E overexpression has also been shown to predict poor outcome in other organ sites including non-small-cell lung carcinoma, squamous cell carcinoma of the larynx and adrenocortical tumors (Dong et al., 2000; Fukuse et al., 2000; Muller-Tidow et al., 2001; Tissier et al., 2004) .
The basis for cyclin E prognostic significance is not known. One possibility is that cyclin E overexpression might simply function as a surrogate for mutations in any part of the p16-cyclinD-Rb-E2F pathway. Since this pathway is mutant in most cancers, cyclin E overexpression should be very common too. Thus, the true utility of cyclin E expression in cancer prognosis may stem from its being a single convenient readout for a complex pathway that can be activated by many different (and difficult to assay) mutations.
Mechanisms of cyclin E-associated tumorigenesis
Early ideas about the role of cyclin E deregulation in cancer focused on the possibility that cancer cells with abnormal cyclin E activity might have reduced mitogen requirements or exhibit other features of unrestrained proliferation, and that this reflected deregulation of the Rb pathway. However, this simple idea is probably not correct and genetic instability has emerged as the likely mechanism through which cyclin E leads to tumorigenesis. The first report of cyclin E-associated genetic instability was from Reed and colleagues, who showed that ectopic cyclin E expression in established rodent and human cancer cell lines caused aneuploidy (Spruck et al., 1999) . Subsequent work showed that cyclin E deregulation also caused genetic instability in primary human cells, but showed that in this case, it was necessary to disable a p53-dependent checkpoint that protects primary cells from excess cyclin E activity (Minella et al., 2002) . In both studies, cyclin E T380A, which resists proteasomal degradation, caused more chromosomal anomalies than wild-type cyclin E. Disruption of the Fbw7 tumor suppressor also generates chromosomal instability, and this may be largely attributable to cyclin E because it was suppressed by siRNA-mediated cyclin E knockdown (Rajagopalan et al., 2004) . Interestingly, Fbw7-null cells exhibited a mitotic defect that was proposed to underlie the genetic instability.
How might excess cyclin E cause genetic instability? One likely mechanism involves defective S-phase progression. S phase is greatly impeded by excess cyclin E activity. This may be due to impaired MCM loading and may lead to instability through several mechanisms. For example, stalled replication forks are probably quite susceptible to breakage. Alternatively, impaired replication may result in cells entering mitosis before their chromosomes are fully replicated, or cause problems with chromosome condensation and pairing. Thus, the mitotic defect observed in Fbw7-null cells could well be due to problems related to S phase rather than a defect in mitosis per se.
Another possible mechanism of cyclin E-associated aneuploidy is centrosome amplification. The role of cyclin E-Cdk2 in centrosome duplication is firmly established in Xenopus extracts (Hinchcliffe et al., 1999; Lacey et al., 1999) . Several papers have implicated cyclin E-Cdk2 in the mammalian centrosome cycle as well (Okuda et al., 2000; Saavedra et al., 2003) , although the absence of reported centrosome and/or spindle anomalies in cyclin E and Cdk2-null animals shows that cyclin E-Cdk2 is not essential for normal centrosome function. Cyclin E overexpression in tissue culture cells, particularly in combination with p53 loss, causes centrosome amplification and aneuploidy, and this is consistent with the possibility that spindle abnormalities due to centrosome amplification contribute to cyclin Einduced aneuploidy (Kawamura et al., 2004) . However, cyclin E-induced genetic instability can occur without obvious spindle defects (Spruck et al., 1999) , and the role of centrosomal anomalies in cyclin E-induced cancer remains controversial.
Models of cyclin E-associated neoplasia
The lack of appropriate animal models has impeded studies of cyclin E-associated cancer. Two animal models of cyclin E-associated cancer have been reported to date. Mice harboring a b-lactoglobulin-cyclin E transgene, which targets expression to mammary glands, develop mammary gland hyperplasia and carcinomas (Bortner and Rosenberg, 1997) . However, cancers develop in only 10% of animals and after a long latent period (8-13 months). Transgenic mice engineered to express cyclin E under the T-cell-specific CD2 promoter do not spontaneously develop lymphomas (Karsunky et al., 1999) , but they develop clonal lymphomas when they are treated with N-methylnitrosourea, or when crossed with p27-null mice (Geisen et al., 2003) . These tumors develop with variable penetrance and latency, and in combination with their clonality, this indicates that cyclin E participates in multistep tumorigenesis, but is not sufficient to induce cancers. The lymphomas exhibited high levels of transgene-directed cyclin ECdk2 activity (compared with normal T cells that also express the transgene), suggesting that additional mutations are required to render the transgene oncogenic. One such event may be Ras activation, and Ki-ras mutations were found in the carcinogen-induced lymphomas. Indeed, the finding that activated Ras cooperates with cyclin E in cotransformation assays utilizing rodent fibroblasts supports the idea that Ras activation and cyclin E deregulation cooperate during tumorigenesis . Interestingly, Martins and Berns (2002) found that p27 loss and a c-myc transgene also cooperatively increased cyclin E-Cdk2 activity in murine lymphomas. Thus, multiple oncogenic events may converge upon cyclin E-Cdk2 during tumorigenesis.
Cyclin E-Cdk2 and cancer therapy
As the downstream effector of many cancer-associated pathways, cyclin E-Cdk2 is an attractive therapeutic target. Although early clinical trials with Cdk inhibitors have not been encouraging, enthusiasm for cancer treatments based on Cdk2 inhibition remains high. Is this enthusiasm justified in light of the realization that cyclin E-Cdk2 is not essential for cell division in mice?
Although many potential obstacles could prevent the development of effective Cdk2-based antineoplastics, the lack of knockout phenotypes in mice is not one. Cyclin E gain-of-function is associated with tumorigenesis, and the fact that cyclin E is dispensable for normal cell division does not imply that reducing its abnormally high activity in cancer cells will be fruitless. In fact, many dominant oncogenes are not essential in normal cells (c-fos, c-src, etc.).
There are, however, several bona fide concerns as to why Cdk2 inhibition may not turn out to be effective cancer therapy. For example, if genetic instability is the sole mechanism linking cyclin E to cancer, then fully established tumors are unlikely to be specifically affected by Cdk2 inhibition. Moreover, despite data indicating that cancer cell lines may be hypersensitive to Cdk inhibition , this has not been shown for primary tumors in patients. Another argument against this therapeutic approach is the finding that human cancer cell lines proliferate when Cdk2 is inhibited by RNA interference (Tetsu and McCormick, 2003) . However, these experiments used established cell lines in short-term assays, and the relevance of these studies to treating patients over extended time periods is unknown. It is clear, however, that much more work is needed before we know if cyclin E-Cdk2's status as a therapeutic target will live up to its early promise, or whether it will suffer the same fate as its 'essential' role in cell division.
